{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "status": "retrieved", "company": "Xbrane Biopharma", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:42:36Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar Delårsrapport januari-juni 2026", "category": "Halvårsrapport", "date": "2026-07-17", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q2", "period": "2026-q2", "report_key": "2026:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf047b993615d2f514f24206cf1fed5fd&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q2\\release.txt", "attachments": [ { "label": "Xbrane Q2 2026 SVE Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8b00b947a5558a7cef2b0564a7b70cac", "final_url": "https://attachment.news.eu.nasdaq.com/a8b00b947a5558a7cef2b0564a7b70cac", "filename": "Xbrane_Q2_2026_SVE_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q2\\Xbrane_Q2_2026_SVE_Final.pdf", "content_type": "application/pdf", "size": 684702, "sha256": "7e3d3748b4c0f10fcbf22c4cb67faf9669e1483be41ef2ce36e7b6f44414b2d3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q2\\Xbrane_Q2_2026_SVE_Final.pdf", "filename": "Xbrane_Q2_2026_SVE_Final.pdf", "extension": ".pdf", "size": 684702, "sha256": "7e3d3748b4c0f10fcbf22c4cb67faf9669e1483be41ef2ce36e7b6f44414b2d3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q2\\extracted\\Xbrane_Q2_2026_SVE_Final\\Xbrane_Q2_2026_SVE_Final.txt", "text_chars": 51755, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q2\\extracted\\Xbrane_Q2_2026_SVE_Final\\Xbrane_Q2_2026_SVE_Final.extraction.json" } } ], "announcement_id": "1454667", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:42:40Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma ABs (publ.) (”Xbrane”) delårsrapport för januari-mars 2026 finns från och med idag tillgänglig på bolagets webbsida, www.xbrane.com.", "category": "Interimsrapport", "date": "2026-05-05", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b230a0183c7f5a68913d1d3421a036d3d&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "Xbrnane Q1 2026 SVE Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/acc297eb055190ad3b4286e211b143166", "final_url": "https://attachment.news.eu.nasdaq.com/acc297eb055190ad3b4286e211b143166", "filename": "Xbrnane_Q1_2026_SVE_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q1\\Xbrnane_Q1_2026_SVE_Final.pdf", "content_type": "application/pdf", "size": 665038, "sha256": "357f9101e71e4b40226b094761e2e48c3bf75479d1e9ee875639dd80adf3ccf2", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q1\\Xbrnane_Q1_2026_SVE_Final.pdf", "filename": "Xbrnane_Q1_2026_SVE_Final.pdf", "extension": ".pdf", "size": 665038, "sha256": "357f9101e71e4b40226b094761e2e48c3bf75479d1e9ee875639dd80adf3ccf2", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\Xbrnane_Q1_2026_SVE_Final\\Xbrnane_Q1_2026_SVE_Final.txt", "text_chars": 45705, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\Xbrnane_Q1_2026_SVE_Final\\Xbrnane_Q1_2026_SVE_Final.extraction.json" } } ], "announcement_id": "1439533", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:42:53Z", "company": "Xbrane Biopharma AB", "title": "Xbrane har publicerat års- och hållbarhetsredovisningen för 2025. Redovisningen sammanfattar affärsverksamhet, finansiellt resultat samt hållbarhetsarbetet.", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-03-31", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba8507658bec6911c1b60778bf56679cf&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "Xbrane AR 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a9d342a40ad1e12dc500324a338e7209f", "final_url": "https://attachment.news.eu.nasdaq.com/a9d342a40ad1e12dc500324a338e7209f", "filename": "Xbrane_AR_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-annual\\Xbrane_AR_2025.pdf", "content_type": "application/pdf", "size": 5365748, "sha256": "fa1e0f6252dbc314c29334cc9f47339e138eda9fe1bbb323c6b6604635fdec75", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-annual\\Xbrane_AR_2025.pdf", "filename": "Xbrane_AR_2025.pdf", "extension": ".pdf", "size": 5365748, "sha256": "fa1e0f6252dbc314c29334cc9f47339e138eda9fe1bbb323c6b6604635fdec75", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\Xbrane_AR_2025\\Xbrane_AR_2025.txt", "text_chars": 343429, "metadata": { "page_count": 84, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\Xbrane_AR_2025\\Xbrane_AR_2025.extraction.json" } } ], "announcement_id": "1430304", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:42:55Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar bokslutskommuniké 2025", "category": "Bokslutskommuniké", "date": "2026-02-20", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4a47b654ab5d44680744f0808f9851fe&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "Xbrane Q4 2025 SV Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a813f72aa1fe1d92f6a7849f53ce18fb2", "final_url": "https://attachment.news.eu.nasdaq.com/a813f72aa1fe1d92f6a7849f53ce18fb2", "filename": "Xbrane_Q4_2025_SV_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q4\\Xbrane_Q4_2025_SV_Final.pdf", "content_type": "application/pdf", "size": 645011, "sha256": "ccb9f087648165009e342257f1663f96082a2f50d5602cc0c5b9c88137520dd3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q4\\Xbrane_Q4_2025_SV_Final.pdf", "filename": "Xbrane_Q4_2025_SV_Final.pdf", "extension": ".pdf", "size": 645011, "sha256": "ccb9f087648165009e342257f1663f96082a2f50d5602cc0c5b9c88137520dd3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\Xbrane_Q4_2025_SV_Final\\Xbrane_Q4_2025_SV_Final.txt", "text_chars": 52117, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\Xbrane_Q4_2025_SV_Final\\Xbrane_Q4_2025_SV_Final.extraction.json" } } ], "announcement_id": "1421561", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:01Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar Delårsrapport januari-September 2025", "category": "Interimsrapport", "date": "2025-10-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b5f3e1a4e564123e3b09c684175fef78e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "Xbrane Biopharma Publicerar Delarsrapport Januari September 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae3a7879bcb3b8d96fb5b9d491e2691eb", "final_url": "https://attachment.news.eu.nasdaq.com/ae3a7879bcb3b8d96fb5b9d491e2691eb", "filename": "Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q3\\Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf", "content_type": "application/pdf", "size": 880455, "sha256": "088aab35dd2d493f1f1dd6900780ae3ccef45d7ecea2df6a44e3e6f956d86223", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q3\\Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf", "filename": "Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf", "extension": ".pdf", "size": 880455, "sha256": "088aab35dd2d493f1f1dd6900780ae3ccef45d7ecea2df6a44e3e6f956d86223", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\Xbrane_Biopharma_Publicerar_Delarsrapport_Jan\\Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_.txt", "text_chars": 53374, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\Xbrane_Biopharma_Publicerar_Delarsrapport_Jan\\Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_.extraction.json" } } ], "announcement_id": "1396460", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:07Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar Delårsrapport januari-juni 2025", "category": "Halvårsrapport", "date": "2025-08-26", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba1ae222d47a4a58091d420b7012f4676&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari Juni 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8b28a04292205e718386a24bd65b425b", "final_url": "https://attachment.news.eu.nasdaq.com/a8b28a04292205e718386a24bd65b425b", "filename": "Xbrane_Delarsrapport_Januari_Juni_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q2\\Xbrane_Delarsrapport_Januari_Juni_2025.pdf", "content_type": "application/pdf", "size": 1367004, "sha256": "5ff496ee4d1781dd51924b3e53802d929b304b3523e29dad66af759ae0b29ee5", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q2\\Xbrane_Delarsrapport_Januari_Juni_2025.pdf", "filename": "Xbrane_Delarsrapport_Januari_Juni_2025.pdf", "extension": ".pdf", "size": 1367004, "sha256": "5ff496ee4d1781dd51924b3e53802d929b304b3523e29dad66af759ae0b29ee5", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\Xbrane_Delarsrapport_Januari_Juni_2025\\Xbrane_Delarsrapport_Januari_Juni_2025.txt", "text_chars": 49294, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\Xbrane_Delarsrapport_Januari_Juni_2025\\Xbrane_Delarsrapport_Januari_Juni_2025.extraction.json" } } ], "announcement_id": "1385209", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:12Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar Delårsrapport januari-mars 2025", "category": "Interimsrapport", "date": "2025-05-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd530eb5ed65bc61b69ca3ae3b699c01e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari Mars 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8c392a9c26ea21acb0666e12bd29d58c", "final_url": "https://attachment.news.eu.nasdaq.com/a8c392a9c26ea21acb0666e12bd29d58c", "filename": "Xbrane_Delarsrapport_Januari_Mars_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q1\\Xbrane_Delarsrapport_Januari_Mars_2025.pdf", "content_type": "application/pdf", "size": 1348750, "sha256": "eebeffba94a890e55b83e3e31b6dae3ec4451ccb469e83db1504d24f6113b139", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q1\\Xbrane_Delarsrapport_Januari_Mars_2025.pdf", "filename": "Xbrane_Delarsrapport_Januari_Mars_2025.pdf", "extension": ".pdf", "size": 1348750, "sha256": "eebeffba94a890e55b83e3e31b6dae3ec4451ccb469e83db1504d24f6113b139", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\Xbrane_Delarsrapport_Januari_Mars_2025\\Xbrane_Delarsrapport_Januari_Mars_2025.txt", "text_chars": 44399, "metadata": { "page_count": 17, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\Xbrane_Delarsrapport_Januari_Mars_2025\\Xbrane_Delarsrapport_Januari_Mars_2025.extraction.json" } } ], "announcement_id": "1361744", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:24Z", "company": "Xbrane Biopharma AB", "title": "XBRANE BIOPHARMA PUBLICERAR ÅRS- OCH HÅLLBARHETSREDOVISNING FÖR 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-03-31", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b58944d561bae385c0d3ce411b2591801&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "Xbrane Ars Och Hallbarhetsredovisning 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a7eef0a3ebf43923dd5572e56af90417c", "final_url": "https://attachment.news.eu.nasdaq.com/a7eef0a3ebf43923dd5572e56af90417c", "filename": "Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-annual\\Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf", "content_type": "application/pdf", "size": 6121682, "sha256": "3f5b5f0e1147f37150907444d67397d2b022ad57ad5be6e7ce0829c99f5313c9", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-annual\\Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf", "filename": "Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf", "extension": ".pdf", "size": 6121682, "sha256": "3f5b5f0e1147f37150907444d67397d2b022ad57ad5be6e7ce0829c99f5313c9", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\Xbrane_Ars_Och_Hallbarhetsredovisning_2024\\Xbrane_Ars_Och_Hallbarhetsredovisning_2024.txt", "text_chars": 325763, "metadata": { "page_count": 80, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\Xbrane_Ars_Och_Hallbarhetsredovisning_2024\\Xbrane_Ars_Och_Hallbarhetsredovisning_2024.extraction.json" } } ], "announcement_id": "1352469", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:27Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar bokslutskommuniké 2024", "category": "Bokslutskommuniké", "date": "2025-02-20", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=be76eea6c6fe702a12e453aa5b0995f24&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "Bokslutskommunike 2024 Xbrane Biopharma.pdf", "url": "https://attachment.news.eu.nasdaq.com/a4d584d783c99dfbd00656a582f145aed", "final_url": "https://attachment.news.eu.nasdaq.com/a4d584d783c99dfbd00656a582f145aed", "filename": "Bokslutskommunike_2024_Xbrane_Biopharma.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q4\\Bokslutskommunike_2024_Xbrane_Biopharma.pdf", "content_type": "application/pdf", "size": 1676826, "sha256": "fabc4c3f648bfaae047c5f1794f2dc75e25771d6b0a6e15aa604843f962b1f70", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q4\\Bokslutskommunike_2024_Xbrane_Biopharma.pdf", "filename": "Bokslutskommunike_2024_Xbrane_Biopharma.pdf", "extension": ".pdf", "size": 1676826, "sha256": "fabc4c3f648bfaae047c5f1794f2dc75e25771d6b0a6e15aa604843f962b1f70", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\Bokslutskommunike_2024_Xbrane_Biopharma\\Bokslutskommunike_2024_Xbrane_Biopharma.txt", "text_chars": 66354, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\Bokslutskommunike_2024_Xbrane_Biopharma\\Bokslutskommunike_2024_Xbrane_Biopharma.extraction.json" } } ], "announcement_id": "1344171", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:32Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar delårsrapport för januari-september 2024", "category": "Interimsrapport", "date": "2024-10-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4b8d3dfe9277505314f56bf7e1d47c5e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari September 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8adcf2134633ef76ecaee3beb2b2afd3", "final_url": "https://attachment.news.eu.nasdaq.com/a8adcf2134633ef76ecaee3beb2b2afd3", "filename": "Xbrane_Delarsrapport_Januari_September_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q3\\Xbrane_Delarsrapport_Januari_September_2024.pdf", "content_type": "application/pdf", "size": 1679228, "sha256": "fea7b56153d5e34d2498ca1265ed60625b390a87c8eaa9af74ea8fe81a6f0601", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q3\\Xbrane_Delarsrapport_Januari_September_2024.pdf", "filename": "Xbrane_Delarsrapport_Januari_September_2024.pdf", "extension": ".pdf", "size": 1679228, "sha256": "fea7b56153d5e34d2498ca1265ed60625b390a87c8eaa9af74ea8fe81a6f0601", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\Xbrane_Delarsrapport_Januari_September_2024\\Xbrane_Delarsrapport_Januari_September_2024.txt", "text_chars": 64031, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\Xbrane_Delarsrapport_Januari_September_2024\\Xbrane_Delarsrapport_Januari_September_2024.extraction.json" } } ], "announcement_id": "1323177", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:38Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar delårsrapport för januari-juni 2024", "category": "Halvårsrapport", "date": "2024-08-28", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4bcb039a935da18c889d6f11d89b3da8&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari Juni 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/afcd1197113fc2b33e83865f022b318ab", "final_url": "https://attachment.news.eu.nasdaq.com/afcd1197113fc2b33e83865f022b318ab", "filename": "Xbrane_Delarsrapport_Januari_Juni_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q2\\Xbrane_Delarsrapport_Januari_Juni_2024.pdf", "content_type": "application/pdf", "size": 2773988, "sha256": "13bfd4d1ca17750edb29ab5cf61d779d4e5b6e69751a3c38c3bd16f89e071875", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q2\\Xbrane_Delarsrapport_Januari_Juni_2024.pdf", "filename": "Xbrane_Delarsrapport_Januari_Juni_2024.pdf", "extension": ".pdf", "size": 2773988, "sha256": "13bfd4d1ca17750edb29ab5cf61d779d4e5b6e69751a3c38c3bd16f89e071875", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\Xbrane_Delarsrapport_Januari_Juni_2024\\Xbrane_Delarsrapport_Januari_Juni_2024.txt", "text_chars": 64019, "metadata": { "page_count": 20, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\Xbrane_Delarsrapport_Januari_Juni_2024\\Xbrane_Delarsrapport_Januari_Juni_2024.extraction.json" } } ], "announcement_id": "1313213", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:43Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar delårsrapport för januari-mars 2024", "category": "Interimsrapport", "date": "2024-05-16", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bbed386060026eb8c6afb9674019aee38&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari Mars 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/af09b23e96b28bf344d5899d50a74609a", "final_url": "https://attachment.news.eu.nasdaq.com/af09b23e96b28bf344d5899d50a74609a", "filename": "Xbrane_Delarsrapport_Januari_Mars_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q1\\Xbrane_Delarsrapport_Januari_Mars_2024.pdf", "content_type": "application/pdf", "size": 740804, "sha256": "f6d05051c23488cb563c691d05a2d6defeec9d034c1b584f3e6cd4eecfea6e12", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q1\\Xbrane_Delarsrapport_Januari_Mars_2024.pdf", "filename": "Xbrane_Delarsrapport_Januari_Mars_2024.pdf", "extension": ".pdf", "size": 740804, "sha256": "f6d05051c23488cb563c691d05a2d6defeec9d034c1b584f3e6cd4eecfea6e12", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\Xbrane_Delarsrapport_Januari_Mars_2024\\Xbrane_Delarsrapport_Januari_Mars_2024.txt", "text_chars": 60276, "metadata": { "page_count": 20, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\Xbrane_Delarsrapport_Januari_Mars_2024\\Xbrane_Delarsrapport_Januari_Mars_2024.extraction.json" } } ], "announcement_id": "1296065", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:57Z", "company": "Xbrane Biopharma AB", "title": "XBRANE BIOPHARMA PUBLICERAR ÅRS- OCH HÅLLBARHETSREDOVISNING FÖR 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-03-27", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2fdf233b6feac2ec5383740bf8723aa3&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "Ars Och Hallbarhetsredovisning 2023 Xbrane Biopharma AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a6856e0b392caa7dc1b69afb9788317fd", "final_url": "https://attachment.news.eu.nasdaq.com/a6856e0b392caa7dc1b69afb9788317fd", "filename": "Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-annual\\Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf", "content_type": "application/pdf", "size": 8497174, "sha256": "f2c82c155bbcd60f120feda5cb54d6785c0f8d90179e7d9d4bccd9c089063e8d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-annual\\Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf", "filename": "Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf", "extension": ".pdf", "size": 8497174, "sha256": "f2c82c155bbcd60f120feda5cb54d6785c0f8d90179e7d9d4bccd9c089063e8d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Bi\\Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biophar.txt", "text_chars": 350135, "metadata": { "page_count": 96, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Bi\\Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biophar.extraction.json" } } ], "announcement_id": "1284440", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:43:59Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar bokslutskommuniké 2023", "category": "Bokslutskommuniké", "date": "2024-02-26", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b154dada9da1be4d45f86322a1eeff6e7&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "Xbrane Bokslutskommunike 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/aae2c3aebe98040e16efe5e5bf4419283", "final_url": "https://attachment.news.eu.nasdaq.com/aae2c3aebe98040e16efe5e5bf4419283", "filename": "Xbrane_Bokslutskommunike_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q4\\Xbrane_Bokslutskommunike_2023.pdf", "content_type": "application/pdf", "size": 1345106, "sha256": "3c0e145ce0ae8ac70264c1582c7127997cae57c2f4d7cc2236db75b7ba49f513", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q4\\Xbrane_Bokslutskommunike_2023.pdf", "filename": "Xbrane_Bokslutskommunike_2023.pdf", "extension": ".pdf", "size": 1345106, "sha256": "3c0e145ce0ae8ac70264c1582c7127997cae57c2f4d7cc2236db75b7ba49f513", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\Xbrane_Bokslutskommunike_2023\\Xbrane_Bokslutskommunike_2023.txt", "text_chars": 62036, "metadata": { "page_count": 20, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\Xbrane_Bokslutskommunike_2023\\Xbrane_Bokslutskommunike_2023.extraction.json" } } ], "announcement_id": "1277200", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:44:08Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar delårsrapport för januari - september 2023", "category": "Interimsrapport", "date": "2023-11-30", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2d386f2113484968b6f3832a3908579d&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "Xbrane Biopharma Q3 2023 Presentation.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3133c77b9220a1f35b8f98bd2e27c665", "final_url": "https://attachment.news.eu.nasdaq.com/a3133c77b9220a1f35b8f98bd2e27c665", "filename": "Xbrane_Biopharma_Q3_2023_Presentation.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\Xbrane_Biopharma_Q3_2023_Presentation.pdf", "content_type": "application/pdf", "size": 2089297, "sha256": "7fed6b3faf9c845bf0580a185815a5ce3f55696942834165c8596af8a3a3d06d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\Xbrane_Biopharma_Q3_2023_Presentation.pdf", "filename": "Xbrane_Biopharma_Q3_2023_Presentation.pdf", "extension": ".pdf", "size": 2089297, "sha256": "7fed6b3faf9c845bf0580a185815a5ce3f55696942834165c8596af8a3a3d06d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\Xbrane_Biopharma_Q3_2023_Presentation\\Xbrane_Biopharma_Q3_2023_Presentation.txt", "text_chars": 8821, "metadata": { "page_count": 19, "empty_pages": 2, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\Xbrane_Biopharma_Q3_2023_Presentation\\Xbrane_Biopharma_Q3_2023_Presentation.extraction.json" } }, { "label": "Xbrane Delarsrapport Janari September 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/abc62f12149e6042fbd3d0330700058f6", "final_url": "https://attachment.news.eu.nasdaq.com/abc62f12149e6042fbd3d0330700058f6", "filename": "Xbrane_Delarsrapport_Janari_September_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\Xbrane_Delarsrapport_Janari_September_2023.pdf", "content_type": "application/pdf", "size": 1351354, "sha256": "b50e5ff5fcedba001dd13b6125e935ddba56e6a47f92c9aacc5eacf1abf426df", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\Xbrane_Delarsrapport_Janari_September_2023.pdf", "filename": "Xbrane_Delarsrapport_Janari_September_2023.pdf", "extension": ".pdf", "size": 1351354, "sha256": "b50e5ff5fcedba001dd13b6125e935ddba56e6a47f92c9aacc5eacf1abf426df", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\Xbrane_Delarsrapport_Janari_September_2023\\Xbrane_Delarsrapport_Janari_September_2023.txt", "text_chars": 65523, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\Xbrane_Delarsrapport_Janari_September_2023\\Xbrane_Delarsrapport_Janari_September_2023.extraction.json" } } ], "announcement_id": "1262074", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:44:13Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar delårsrapport för januari - juni 2023", "category": "Halvårsrapport", "date": "2023-08-29", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd15a1d16d5dd0155a56e66ae6120354a&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari Juni 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a69952714f15e9944fee6cea540351063", "final_url": "https://attachment.news.eu.nasdaq.com/a69952714f15e9944fee6cea540351063", "filename": "Xbrane_Delarsrapport_Januari_Juni_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q2\\Xbrane_Delarsrapport_Januari_Juni_2023.pdf", "content_type": "application/pdf", "size": 1448927, "sha256": "3bc9b51984690eb69acda822fed28ad70573c71682bb3fdf177c9f11c46934dd", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q2\\Xbrane_Delarsrapport_Januari_Juni_2023.pdf", "filename": "Xbrane_Delarsrapport_Januari_Juni_2023.pdf", "extension": ".pdf", "size": 1448927, "sha256": "3bc9b51984690eb69acda822fed28ad70573c71682bb3fdf177c9f11c46934dd", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\Xbrane_Delarsrapport_Januari_Juni_2023\\Xbrane_Delarsrapport_Januari_Juni_2023.txt", "text_chars": 67811, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\Xbrane_Delarsrapport_Januari_Juni_2023\\Xbrane_Delarsrapport_Januari_Juni_2023.extraction.json" } } ], "announcement_id": "1244977", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:44:17Z", "company": "Xbrane Biopharma AB", "title": "Xbrane Biopharma publicerar delårsrapport för januari - mars 2023", "category": "Interimsrapport", "date": "2023-05-31", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b36ceb6f7136d8f194bebbb0d3f2da048&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "Xbrane Delarsrapport Januari Mars 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a7e48fde7152361f229b91537d0dfb244", "final_url": "https://attachment.news.eu.nasdaq.com/a7e48fde7152361f229b91537d0dfb244", "filename": "Xbrane_Delarsrapport_Januari_Mars_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q1\\Xbrane_Delarsrapport_Januari_Mars_2023.pdf", "content_type": "application/pdf", "size": 1432586, "sha256": "cd9946c616fd15ef5bca6abaaf5a535bf592b856e067f4f2d356e83adff960d0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q1\\Xbrane_Delarsrapport_Januari_Mars_2023.pdf", "filename": "Xbrane_Delarsrapport_Januari_Mars_2023.pdf", "extension": ".pdf", "size": 1432586, "sha256": "cd9946c616fd15ef5bca6abaaf5a535bf592b856e067f4f2d356e83adff960d0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\Xbrane_Delarsrapport_Januari_Mars_2023\\Xbrane_Delarsrapport_Januari_Mars_2023.txt", "text_chars": 62648, "metadata": { "page_count": 21, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xbrane-biopharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\Xbrane_Delarsrapport_Januari_Mars_2023\\Xbrane_Delarsrapport_Januari_Mars_2023.extraction.json" } } ], "announcement_id": "1231070", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "aa5254315f0967d2fcf43c69a1e39b662117285a550230e1c583a181d72c87b5" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "48c4a5ad739a983e9570439c66dee95920ca918c748d64ee9ff516386ff19ada" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "d7d89e76160e2aba66ce07fc2c7d6c6d8009f9873b83c9a124db04aa2c08a050" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=300&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 300, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 16, "new_rows": 16, "total_count": null, "from_cache": false, "body_sha256": "3b7ef3881079163b9e60b31c2e7cb2383546bdf006bcedb3d933033606ffc31a" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=316&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 316, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "3d6a3e93f6e09a949fbe42baf0f55eebb0091102f6573bb421181bc4da80979c" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 4, "new_rows": 4, "total_count": null, "from_cache": false, "body_sha256": "92fb55f0436d0f396adde5288d94fd2b0bed9dbd62d2a98bcdcf8d801350c322" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=4&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 4, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e27b60cb74ad0e336cee9c3aa3436314395a27959baa132e37b1113a29192eb8" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "a3c450c52d5db577f765c50d85d9426efa03a181503e62fc9a4ad274007601f4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "21182e15d781e9145dea4b6018644ca50ea9e66f0d328bf9b18f76003882c647" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "1056b65cd71312279e2c937aa8927a07387a529622781185ef6a788d77a5da4b" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=300&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 300, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 21, "new_rows": 21, "total_count": null, "from_cache": false, "body_sha256": "78283ce308e59f3d30f2956541c95f186d87381dee90b3c4d16e0d7e29da6929" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=321&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 321, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "7b9acf077446603e664a9d5515a1cd1f7cf3ed09a62a876dc746f1e70a7d1745" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 3, "new_rows": 3, "total_count": null, "from_cache": false, "body_sha256": "a27d6a1961df631ddb0d838110f17bd4d7e9224fe35f783d24c4cffa0f7f56a4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Xbrane+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=3&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 3, "pagination": "row-offset", "query_text": "Xbrane Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "449de37c3458e07fa7a04e480e0ef1298d825283b8c7f36964108a8672015b9a" } ], "identity": { "slug": "", "instrument_id": "TX1981696", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/xbrane?id=TX1981696" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Xbrane Biopharma", "retrieved_at": "2026-08-07T08:44:18Z" }